{
    "nct_id": "NCT06554639",
    "official_title": "A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effects of Multiple Doses of Diltiazem on the Single-Dose Pharmacokinetics of MK-5684 in Healthy Adult Male Participants",
    "inclusion_criteria": "The main inclusion criteria include but are not limited to the following:\n\n* Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to the first dosing based on participant self-reporting\n* Body mass index (BMI) ≥18.0 and ≤32.0 kg/m^2\n* Able to swallow multiple tablets\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years\nMust have maximum age of 55 Years",
    "exclusion_criteria": "The main exclusion criteria include but are not limited to the following:\n\n* History or presence of any of the following:\n\n  * Adrenal insufficiency\n  * Hepatic or renal impairment\n  * Clinically significant hypotension, cardiac arrhythmia, cardiac conduction abnormalities, or recurrent unexplained syncopal events\n  * Second- or third-degree Atrioventricular (AV) heart block (except in participants with a functional artificial pacemaker)\n  * Clinically significant sick sinus syndrome\n  * Presence of any systemic fungal infection\n  * Chronic infection\n  * Glaucoma\n  * Hypothyroidism\n  * Stomach ulcer\n  * Ocular herpes simplex\n* Has a first-degree relative with multiple unexplained syncopal events, unexplained cardiac arrest, or sudden cardiac death, or has a known family history of an inherited arrhythmia syndrome (including Brugada syndrome)\n* History of cancer (malignancy)\n* Unable to refrain from or anticipants the use of: Unable to refrain from or anticipates the use of: Any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to the first dosing",
    "miscellaneous_criteria": ""
}